According to existing studies, it is found that SLC2A3 has a high affinity for glucose, which can ensure the effective uptake of glucose by cells (Simpson et al., 2008), and the low expression of KMT2D significantly affects the effect of SLC2A3, thereby inhibiting cancer cells’ uptake and utilization of glucose. The gene discussed is KMT2D; the disease is cancer.